Astrazeneca PLC ORD SHS $0.25
Astrazeneca PLC ORD SHS $0.25/ GB0009895292 /
AZN
2024-05-17 5:51:06 PM
|
Chg.
-56.0000
|
Volume |
Bid6:30:00 PM |
Ask6:30:00 PM |
Market Capitalization |
Dividend Y. |
P/E Ratio |
12,110.0000GBX
|
-0.46%
|
1.68 mill. Turnover(GBP): 165.03 mill. |
11,600.0000Bid Size: 100 |
12,470.0000Ask Size: 500 |
187.14 bill.GBP |
- |
- |
Business description
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
Management board & Supervisory board
CEO |
Pascal Soriot |
Management board |
Aradhana Sarin, Pam Cheng, Ruud Dobber, Marc Dunoyer, David Fredrickson, Susan Galbraith, Menelas (Mene) Pangalos, Jeff Pott, Iskra Reic, Leon Wang, Sharon Barr |
Supervisory board |
Michel Demaré, Pascal Soriot, Aradhana Sarin, Philip Broadley, Euan Ashley, Deborah DiSanzo, Diana Layfield, Sheri McCoy, Tony Mok, Nazneen Rahman, Andreas Rummelt, Marcus Wallenberg |
Company calendar
CW 30 | 2024-07-25
Interim Report 2nd Quarter/6 Months
|
CW 32 | 2024-08-08
Ex-Dividend
|
CW 32 | 2024-08-09
Record Date
|
CW 37 | 2024-09-09
Dividend Payment
|
CW 46 | 2024-11-12
Interim Report 3rd Quarter/9 Months
|